Telbivudine: a new option for the treatment of chronic hepatitis B

Bibliography

• GANEM D, PRINCE A: Hepatitis B virus infection – natural history and clinical consequences. N. Engl. J. Med. (2004) 350(11):1118-1129.
   PubMed Web of Science ®Google Scholar
• FARRINGTON L, HUTIN Y, BELL B: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol. (2006) 45(4):529-538.
   PubMed Web of Science ®Google Scholar
• LOK A, MCMAHON J: Chronic hepatitis B. Hepatology (2007) 45(2):507-539.
   PubMed Web of Science ®Google Scholar
• TASSOPOULOS N, PAPAEVANGELOU G, SJOGREN M, ROUMELIOTOU-KARAYANNIS A, GERIN J, PURCELL R: Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology (1987) 92(6):1844-1850.
   PubMed Web of Science ®Google Scholar
• LIAW Y, TAI D, CHU C, CHEN T: The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology (1988) 8(3):493-496.
   PubMed Web of Science ®Google Scholar
• FATTOVICH G: Natural history of hepatitis B. J. Hepatol. (2003) 39(Suppl. 1):50-58.
   PubMed Web of Science ®Google Scholar
• BEASLEY R: Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer (1988) 61(10):1942-1956.
   PubMed Web of Science ®Google Scholar
• FATTOVICH G, BROLLO L, GIUSTINA G et al.: Natural history and prognostic factors of chronic hepatitis type B. Gut (1991) 32:294-298.
   PubMed Web of Science ®Google Scholar
• FATTOVICH G, GISUTINA G, REALDI G, CORROCHER R, SCHALM S: Long term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alpha. Hepatology (1997) 26(5):1338-1342.
   PubMed Web of Science ®Google Scholar
• YANG H, LU S, LIAW Y et al.: Hepatitis B e antigen and the risk of hepatocellular carcinoma. Taiwan Community-Based Cancer Screening Project Group. N. Engl. J. Med. (2002) 347:168-174.
   PubMed Web of Science ®Google Scholar
• OHKUBO K, KATO Y, ICHIKAWA T et al.: Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma. Cancer (2002) 94:2663-2668.
   PubMed Web of Science ®Google Scholar
• MOMMEJA-MARIN H, MONDOU E, BLUM MR, ROUSSEAU F: Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology (2003) 37(6):1309-1319.
   PubMed Web of Science ®Google Scholar
• COLIN J, CAZALS-HATEM D, LORIOT M et al.: Influence of HIV infection on chronic hepatitis B in homosexual men. Hepatology (1999) 29(4):1306-1310.
   PubMed Web of Science ®Google Scholar
• IKEDA K, SAITOH S, SUZUKI Y et al.: Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation in 2215 patients. J. Hepatol. (1998) 28(6):930-938.
   PubMed Web of Science ®Google Scholar
• SAGNELLI E, COPPOLA N, SCOLATICO C et al.: Virologic and clinical expression of reciprocal inhibitory effect of hepatitis B, C and delta viruses in patients with chronic hepatitis. Hepatology (2000) 32(5):1106-1110.
   PubMed Web of Science ®Google Scholar
• SORIANO V, PUOTI M, BONACINI M et al.: Care of patients with chronic hepatitis B and HIV coinfection. Recommendations from an HIV-HBV international panel. AIDS (2005) 19:221-240.
   PubMed Web of Science ®Google Scholar
• ILOEJE U, YANG H, SU J et al.: Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology (2006) 130(3):678-686.
   PubMed Web of Science ®Google Scholar
• FATTOVICH G, PANTALENA M, ZAGNI I et al.: Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am. J. Gastroenterol. (2002) 97(11):2886-2895.
   PubMed Web of Science ®Google Scholar
• CHEN C, YANG H, SU J et al.: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA (2006) 295:65-73.
   PubMed Web of Science ®Google Scholar
• LIAW Y, LEUNG N, GUAN R, LAU G, MERICAN I: Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J. Gastroenterol. Hepatol. (2003) 18(3):239-245.
   PubMed Web of Science ®Google Scholar
• YUEN M, SABLON E, HUI C, YUAN H, DECRAEMER H, LAI C: Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology (2001) 34(4):785-791.
   PubMed Web of Science ®Google Scholar
• GAUTHIER J, BOURNE E, LUTZ M et al.: Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J. Infect. Dis. (1999) 180:1757-1762.
   PubMed Web of Science ®Google Scholar
• PUCHHAMMER-STOCKL E, MANDL C, KLETZMAYR J et al.: Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy. J. Infect. Dis. (2000) 181(6):2063-2066.
   PubMed Web of Science ®Google Scholar
• NOVARTIS PHARMACEUTICALSCORP.: TYZEKA (telbivudine) Tablets. Prescribing Information. Cambridge, MA, USA; Idenix Pharmaceuticals, Inc., East Hanover, NJ, USA (2006).
   Google Scholar
• WONG D, CHEUNG A, O’ROURKE K, NAYLOR C, DETSKY A, HEATHCOTE J: Effect of alpha-interferon in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann. Intern. Med. (1993) 119:312-323.
   PubMed Web of Science ®Google Scholar
• PERRILLO R, SCHIFF E, DAVIS G et al.: A randomized controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N. Engl. J. Med. (1990) 323:295-301.
   PubMed Web of Science ®Google Scholar
• JANSSEN H, VAN ZONNEVELD M, SENTURK H et al.: Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet (2005) 365(9495):123-129.
   PubMed Web of Science ®Google Scholar
• MARCELLIN P, LAU G, BONINO F et al.: Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. (2004) 351:1206-1217.
   PubMed Web of Science ®Google Scholar
• HACHÉ C, VILLANEUVE J: Lamivudine treatment in patients with chronic hepatitis B and cirrhosis. Expert Opin. Pharmacother. (2006) 7(13):1835-1843.
   PubMed Web of Science ®Google Scholar
• DIENSTAG J, SCHIFF E, WRIGHT T et al.: Lamivudine as initial treatment for chronic hepatitis B in the United Stages. N. Engl. J. Med. (1999) 341(17):1256-1263.
   PubMed Web of Science ®Google Scholar
• LIAW Y, LEUNG N, CHANG T et al.: Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology (2000) 119(1):172-180.
   PubMed Web of Science ®Google Scholar
• HONKOOP P, DE MAN RA, NIESTERS H, ZONDERVAN P, SCHAM S: Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology (2000) 32(3):635-639.
   PubMed Web of Science ®Google Scholar
• MARCELLIN P, CHANG T, LIM S et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. (2003) 348:808-816.
   PubMed Web of Science ®Google Scholar
• HADZIYANNIS S, TASSOPOULOS N, HEATHCOTE J et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. (2003) 348:800-807.
   PubMed Web of Science ®Google Scholar
• HADZIYANNIS S, TASSOPOULUS N, TING-TSUNG C et al.: Long term adefovir dipivoxil treatment with HBeAg-negative chronic hepatitis B: results after 5 years of therapy. Hepatology (2005) 42:754A.
   Google Scholar
• SCHILDGEN O, SIRMA H, FUNK A et al.: Variant of hepatitis B virus with primary resistance to adefovir. N. Engl. J. Med. (2006) 354:1807-1812.
   PubMed Web of Science ®Google Scholar
• CHANG T, LAI C, SCHILDGEN O, SIRMA H, GERLICH W: Hepatitis B virus with primary resistance to adefovir. N. Engl. J. Med. (2006) 355:322-323.
   PubMed Web of Science ®Google Scholar
• CHILDGEN O, SCHEWE C, VOGEL M et al.: Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment. AIDS (2004) 18:2325-2327.
   PubMed Web of Science ®Google Scholar
• SEIFER M, HAMATAKE R, COLONNO R, STRANDING D: In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob. Agents Chemother. (1998) 42:3200-3208.
   PubMed Web of Science ®Google Scholar
• CHANG T, GISH R, DE MAN R et al.: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. (2006) 354:1001-1010.
   PubMed Web of Science ®Google Scholar
• LAI C, SHOUVAL D, LOK A et al.: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. (2006) 354:1011-1020.
   PubMed Web of Science ®Google Scholar
• TENNEY D, LEVINE S, ROSE R et al.: Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob. Agents Chemother. (2004) 48:3498-3507.
   PubMed Web of Science ®Google Scholar
• YANG H, QI X, SABOGAL A, MILLER M, XIONG S, DELANEY W: Cross-resistance testing of next generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antiviral Ther. (2005) 10(5):625-633.
   PubMed Web of Science ®Google Scholar
• SHELDON J, RODES B, ZOULIM F, BARTHOLOMEUSZ A, SORIANO V: Mutations affecting the replication capacity of the hepatitis B virus. J. Viral Hepat. (2006) 13(7):427-434.
   PubMed Web of Science ®Google Scholar
• BRYANT M, BRIDGES E, PLACIDI L et al.: Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob. Agents Chemother. (2001) 45:229-235.
   PubMed Web of Science ®Google Scholar
• HERNANDEZ-SANTIAGO B, PLACIDI L, CRETON-SCOTT E et al.: Pharmacology of β-L-thymidine and β-L-2´-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus. Antimicrob. Agents Chemother. (2002) 46:1728-1733.
   PubMed Web of Science ®Google Scholar
• SEIFER M, PATTY A, DUKHAN D et al.: Telbivudine (LdT) preferentially inhibits second(+) strand HBV DNA synthesis. J. Hepatol. (2005) 42(Suppl. 2):151.
   Google Scholar
• SEMIZAROV D, ARZUMANOV A, DYATKINA N et al.: Stereoisomers of deoxynucleoside 5’-triphosphates as substrates for template-dependent and-independent DNA polymerase. J. Biol. Chem. (1997) 272:9556-9560.
   PubMed Web of Science ®Google Scholar
• BRINKMAN K, SMEITINK J, ROMIJN J, REISS P: Mitochondrial toxicity induced by nucleoside analogue reverse transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral therapy-related lipodystrophy. Lancet (1999) 354:1112-1115.
   PubMed Web of Science ®Google Scholar
• LAI C, LIM S, BROWN N et al.: A dose-finding study of once-daily oral telbivudine (LdT) in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology (2004) 40(3):719-726.
   PubMed Web of Science ®Google Scholar
• ZHOU X, LIM S, LLOYD D, CHAO G, BROWN N, LAI C: Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications. Antimicrob. Agents Chemother. (2006) 50:874-879.
   Web of Science ®Google Scholar
• HU P, JIANG J, WANG H et al.: Single-dose and multiple-dose pharmacokinetics and safety of telbivudine after oral administration in healthy Chinese subjects. J. Clin. Pharmacol. (2006) 46:999-1007.
   PubMed Web of Science ®Google Scholar
• ZHOU X, LLOYD D, CHAO G, BROWN N: Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects. J. Clin. Pharmacol. (2006) 46:275-281.
   PubMed Web of Science ®Google Scholar
• ZHOU X, FIELMAN B, LLOYD D, CHAO G, BROWN N: Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil. Antimicrob. Agents Chemother. (2006) 50:2309-2315.
   PubMed Web of Science ®Google Scholar
• ZHOU X, MYERS M, CHAO, G, DUBUC G, BROWN N: Clinical pharmacokinetics of telbivudine, a potent antiviral for hepatitis B, in subject with impaired hepatic or renal function. J. Hepatol. (2004) 40(Suppl. 1):134.
   Google Scholar
• WOLTERS L, HANSEN B, NIESTERS H, DE HERTOGH D, DE MAN R: Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J. Hepatol. (2002) 37:137-144.
   PubMed Web of Science ®Google Scholar
• LAI C, LEUNG N, TEO E et al.: A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology (2005) 129:528-536.
   PubMed Web of Science ®Google Scholar
• POYNARD T, LAI C, LEUNG N et al.: Improving antiviral therapy in chronic hepatitis B: maximal viral suppression at week 24 correlates with better clinical efficacy at one year. J. Hepatol. (2004) 40(Suppl. 1):130.
   Google Scholar
• LAI C, GANE E, HSU C et al.: Results of the GLOBE study. Proceedings of the 57th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, USA (27 – 31 October 2006) Abstract 91.
   Google Scholar
• LIAW YF, LEUNG N, GUAN R et al.: Asian-Pacific Consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int. (2005) 25:472-489.
   PubMed Web of Science ®Google Scholar
• LOK A, MCMAHON B: Chronic hepatitis B – AASLD Practice Guidelines. Hepatology (2001) 34:1225-1241.
   PubMed Web of Science ®Google Scholar
• STANDRING D, SEIFER M, PATTY A et al.: HBV resistance determination from the telbivudine GLOBE registration trial. J. Hepatol. (2006) 44(Suppl. 2):191.
   Google Scholar
• HOU J, YIN Y, XU D et al.: A Phase III comparative trial of telbivudine and lamivudine for treatment for chronic hepatitis B in Chinese patients: first year results (abstract). J. Gastroenterol. Hepatol. (2006) 21(Suppl. 2):128-129.
   Google Scholar
• HEATHCOTE J, CHAN H, CHO M et al.: A randomized trial of telbivudine (LdT) versus adefovir for HBeAg-positive chronic hepatitis B. Results of the primary week 24 analysis (abstract). Gastroenterology (2006) 130(Suppl. 2):765.
   Google Scholar